Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicolas Leupin

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2020
First-in-Human Phase I Study of MP0250, a First-in-Class DARPin Drug Candidate Targeting VEGF and HGF, in Patients With Advanced Solid TumorsRichard D Baird, Constanza Linossi, Mark Middleton, et al.
The Journal of Clinical Investigation|July 25, 2018
Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humansPeter Ulrichts, Antonio Guglietta, Torsten Dreier, et al.
American Journal of Hematology|December 11, 2019
Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopeniaAdrian C Newland, Blanca Sánchez-González, László Rejtő, et al.
Blood|August 15, 2002
A high-resolution allelotype of B-cell chronic lymphocytic leukemia (B-CLL)Urban Novak, Elisabeth Oppliger Leibundgut, Jörg Hager, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2017
Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced MalignanciesPhilippe Aftimos, Christian Rolfo, Sylvie Rottey, et al.
Ejhaem|October 17, 2024
A phase 1b/2 study evaluating efficacy and safety of MP0250, a designed ankyrin repeat protein (DARPin) simultaneously targeting vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), in combination with bortezomib and dexamethasone, in patients with relapsed or refractory multiple myelomaStefan Knop, Monika Szarejko, Norbert Grząśko, et al.
Nature Medicine|July 1, 2020
Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agentsCarsten Riether, Thomas Pabst, Sabine Höpner, et al.
Neurology|May 24, 2019
Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravisJames F Howard, Vera Bril, Ted M Burns, et al.
Haematologica|December 15, 2015
Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myelomaMeletios A Dimopoulos, Matthew C Cheung, Murielle Roussel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 22, 2016
Updated Outcomes and Impact of Age With Lenalidomide and Low-Dose Dexamethasone or Melphalan, Prednisone, and Thalidomide in the Randomized, Phase III FIRST TrialCyrille Hulin, Andrew Belch, Chaim Shustik, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2020
First-in-Human Phase I Study of MP0250, a First-in-Class DARPin Drug Candidate Targeting VEGF and HGF, in Patients With Advanced Solid TumorsRichard D Baird, Constanza Linossi, Mark Middleton, et al.
The Journal of Clinical Investigation|July 25, 2018
Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humansPeter Ulrichts, Antonio Guglietta, Torsten Dreier, et al.
American Journal of Hematology|December 11, 2019
Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopeniaAdrian C Newland, Blanca Sánchez-González, László Rejtő, et al.
Blood|August 15, 2002
A high-resolution allelotype of B-cell chronic lymphocytic leukemia (B-CLL)Urban Novak, Elisabeth Oppliger Leibundgut, Jörg Hager, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2017
Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced MalignanciesPhilippe Aftimos, Christian Rolfo, Sylvie Rottey, et al.
Ejhaem|October 17, 2024
A phase 1b/2 study evaluating efficacy and safety of MP0250, a designed ankyrin repeat protein (DARPin) simultaneously targeting vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), in combination with bortezomib and dexamethasone, in patients with relapsed or refractory multiple myelomaStefan Knop, Monika Szarejko, Norbert Grząśko, et al.
Nature Medicine|July 1, 2020
Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agentsCarsten Riether, Thomas Pabst, Sabine Höpner, et al.
Neurology|May 24, 2019
Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravisJames F Howard, Vera Bril, Ted M Burns, et al.
Haematologica|December 15, 2015
Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myelomaMeletios A Dimopoulos, Matthew C Cheung, Murielle Roussel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 22, 2016
Updated Outcomes and Impact of Age With Lenalidomide and Low-Dose Dexamethasone or Melphalan, Prednisone, and Thalidomide in the Randomized, Phase III FIRST TrialCyrille Hulin, Andrew Belch, Chaim Shustik, et al.
Pageof 3